Research and Clinical Trials

Brief Description  

The purpose of this study is to assess the safety and efficacy of LY2140023 (flexibly dosed between 20 and 80 mg BID) in patients with schizophrenia. An active control, aripiprazole (flexibly dosed between 10 and 30 mg/day), is included for comparison. The primary outcome measure will be mean weight change.

Who may be Eligible  

Male or female 18 to 65 with a diagnosis of Schizophrenia.

Speciality/Disorder  

Schizophrenia

IRB Number  

CHS1-11-094

Principal Investigator  

Tcheremissine, Oleg

For More Information, Contact  Dineen  , Gardner
Phone:  (704) 446-7511  Fax:  (704) 446-7506  
Email:  dineen.gardner@atriumhealth.org
Address:465 North Wendover Road Charlotte, NC 28211